Interventional {{label}}

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients


{{trial.Sponsor}} {{trial.Sponsor}}
Approved by FDA
Approved outside USA
Is a supplement


Enrollment Criteria

{{trial.ExternalId}} (First Published: {{trial.FirstPublishedDate|date}} on {{trial.SourceName}})
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Masitinib is a selective, oral tyrosine kinase inhibitor with neuroprotective capability demonstrated via numerous preclinical studies. Two of masitinib's main cellular targets are the mast cell and microglia cell. It is well-established that mast cells play a prominent role in neuroinflammatory processes. Microglia, resident immune cells of the central nervous system (CNS), also constitute an important source of neuroinflammatory mediators and may have fundamental roles in numerous neurodegenerative disorders. The development of masitinib in ALS is therefore based on the pharmacological action of masitinib in microglia cells and mast cells, thereby slowing microglial-related disease progression, reducing neuro-inflammation, and modulating the neuronal microenvironment in both central and peripheral nervous systems. This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group (two ascending dose titrations of masitinib and matching placebo), comparative study of oral masitinib in the treatment of patients with amyotrophic lateral sclerosis (ALS).

Main inclusion criteria include:
- Patients diagnosed with laboratory supported probable, clinically probable or definite
ALS according to the World Federation of Neurology Revised El Escorial criteria
- Patient with a familial or sporadic ALS
- ALS disease duration from diagnosis no longer than 24 months at the screening visit
- Patient treated with a stable dose of riluzole (100 mg/day) for at least 12 weeks days
prior to the baseline visit
- Patient with an ALSFRS-R score progression between onset of the disease and screening
of > 0.3 per month, confirmed with an ALSFRS-R score progression of ≥ 1 point during a
12-week run-in period between screening and randomization.
- Patient with a score, at screening, of at least 26 overall, including a score of at
least 3 on item #3 and at least 2 on each of the 12 ALSFRS-R individual component
items and with a score, at randomization, of at least 2 on each of the 12 ALSFRS-R
individual component items

Main exclusion criteria include:
- Patient with dementia or significant neurological, psychiatric, systemic or organic
disease, uncontrolled or that may interfere with the conduct of the trial or its
- Patient with a FVC < 60% predicted normal value for gender, height, and age at
screening and baseline
- Pregnant, or nursing female patient

{{location.City !== '' ? location.City + ',' : ''}} {{location.RegionAbbreviation}} {{location.PostalCode}} {{location.Country}}
{{location.Facility !== '' ? location.Facility + ',' : ''}} {{location.City !== '' ? location.City + ',' : ''}} {{location.RegionAbbreviation}} {{location.PostalCode}} {{location.Country}}
Location Contact: {{location.Contact.Name}} {{location.Contact.Name}} Phone: {{location.Contact.Phone}}
Join the ALS Research Collaborative (ARC) Study Today!
Ready to make a difference in ALS research?
Join the ARC Study! Whether you're living with ALS or an asymptomatic gene carrier, your participation can help inform ALS research and lead to new treatments.
ALS Research Collaborative
Thank You to Our Sponsors
Mitsubishi Tanabe Pharma